WuXi Biologics remains in Hang Seng ESG 50 Index after latest sustainability review

WuXi Biologics will remain in the Hang Seng ESG 50 Index. * It will also stay in the Hang Seng Corporate Sustainability Benchmark Index. The inclusions follow an A+ rating in the Hong Kong Quality Assurance Agency’s 2026 sustainability assessment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics (Cayman) Inc. published the original content used to generate this news brief via (Ref. ID: 202610140736PR_NEWS_USPR_____CN72056) on October 14, 2026, and is solely responsible for the information contained therein. (C)